who look fit can have signifi cant disabil ity and/or complex medical conditions. The clinician relies on his/her ability to establish any such information via a thorough and sensitive medical history and through liaison with the patient's general medical practitioner. This arti cle considers four circumstances where patients have 'hidden' conditions that it is important for the dentist to know about in order to prevent complications as a result of dental treatment. It consid ers people with epilepsy, latex allergy, acquired or inherited bleeding disorders and those people being treated with oral or intravenous bisphosphonates. Know ing that the patient has a particular condition, its features, how it impacts on oral health, how dental treatment may impact on the condition, and how to modify treatment accordingly means that in many cases these patients can be treated in general dental practice with out any cause for concern. Nevertheless, the occasional medical emergency may still occur and ensuring that the dental team knows how to manage such a situ ation can be life-saving.
EPILEPSY
Epilepsy is common. Whilst not a con dition in its own right, it is a symptom of an underlying neurological disorder. 1 The lifetime risk of developing epilepsy is 2-5%, with people from socio-eco nomically deprived backgrounds more likely to develop it. 2 Its aetiology is related to individual susceptibility, known as the 'seizure threshold', and its dynamic interaction with 'seizure precipitants' or 'triggers'. Seventy percent of epilepsy is idiopathic in origin due to genetic factors such as increased neuronal excitability, meta bolic disorders of cerebral neurones and decreased inhibition of the motor cortex. 1, [3] [4] [5] The remaining 30% may be secondary to underlying intra-cra nial causes, such as space-occupying lesions, trauma, vascular defects, infec tions and cerebral palsy; and systemic causes, such as hypoxia, hypoglycae mia, metabolic causes, alcohol, opiates and barbiturates. 1, [3] [4] [5] The clinical manifestations of seizures vary and reflect the functions of the area of the cortex in which the excessive dis charge of neurones arises and to which it spreads. 6 Epilepsy may be broadly classi fi ed into three main groups (see Table 1 ) based on clinical criteria, seizure char acteristics and confirmation by CT and EEG. 8 Epilepsy can affect the level of consciousness, movement and sensation, and/or result in autonomic or psychic phenomena. 5 Seizures are usually brief and may last from a few seconds to a few minutes. Generally, they have a sud- Table 1 The main types of epileptic seizures and their features den onset, a spontaneous end point and are frequently followed by a 'post-ictal period' of drowsiness and confusion. 1 Some seizures are preceded by an 'aura', for example hallucinations, disorienta tion, slurring of speech, rapid blinking or changes in mood or behaviour.
5

Management
The prognosis of epilepsy is infl uenced by the underlying disease and the sever ity and frequency of the seizures. Its management is primarily medical and, despite extensive research, often the most appropriate regime for an individ ual can only be established by trial and error. Drugs are selected primarily on the basis of the type of seizure (see Table  2 ), starting with a low dose of a single, first-line drug and gradually increasing it until seizure control is achieved. If this is unsuccessful, a second fi rst-line drug is introduced, while the original drug is gradually withdrawn to prevent rebound seizures. 7 If this is still unsuc cessful, then either two fi rst-line drugs are used simultaneously or a second-line drug is tried.
There are an estimated 160,000 peo ple in the UK with epilepsy who require continuing medical treatment. Well managed medication programmes keep about 70% of people with epilepsy sei zure free, however 25,000 of them will have more than one major seizure a month and 60,000 will have more than one minor attack a month. Additionally, there are a further 20,000 patients with severe epilepsy and additional disabili ties who may require institutional or community-based care. 8 
Considerations for oral care
Most people who have seizure disor ders attain good seizure control and are capable of receiving routine dental care in general dental practice. 3 Despite this, some dental professionals may still have concerns about treating people with epi lepsy, generally due to uncertainty about when the individual has seizures. 3 Gen erally, any such anxieties can be allayed by gathering the right information from the patient. However, an empathic and astute approach needs to be taken to • The type and aetiology of seizures
• Any known seizure triggers
• Are any triggers associated with dental care, eg stress, light, infections
• Details of any auras experienced
• Does the aura always progress to a seizure • What to expect when the person has a seizure, eg speed of onset, symptoms, usual length of seizure, speed of recovery
• The date of the last seizure
• 
Seizure history
A thorough medical and seizure history provides information about the seizures and their control that helps the practi tioner in the scheduling and planning of appropriate dental treatment. 1 Table  3 sets out the areas that should be cov ered in the seizure history. Particularly important are the drug history, which should be checked at each visit; the type, severity and frequency of seizures, to establish if the person is in a good phase or not; and identifi cation of sei zure precipitants or triggers so that they can be avoided or minimised during dental treatment. The drug history gives some indication of the degree of seizure control. Frequent medication changes suggest that seizures are not optimally controlled, 4 and in this situation it may be prudent to delay non-urgent dental care until seizure control is stable or to refer the patient for specialist care. 3 As a matter of routine, it is advisable to check that the person has taken their routine anti-epilepsy medication, has their emergency medication with them, is well, is not excessively tired and has eaten as usual before embarking on any treatment. 1 It is prudent to advise the patient to cancel the appointment if they feel that their seizures are poorly con trolled on the day of an appointment, as the added stress of dental treatment may trigger a seizure. 5 
Drug therapy
A number of drugs used in seizure con trol have implications for oral care or dental treatment. Gingival hyperplasia associated with phenytoin remains the most widely known complication, even though it is no longer a fi rst-line drug (Fig. 1) . Reports claim that 50% of indi viduals are affected within three to six 9 months of starting therapy, and ado lescents are at particular risk. 10 Whilst the relationship between gingival over growth seems to be related to plasma phenytoin levels, 11 there is a clear rela tionship with oral hygiene, 1, 12, 13 although there is a genetic link that protects some people, even with very poor oral hygiene, from developing the condition.
14 Gin gival overgrowth is reported to resolve spontaneously in 1-6 months following phenytoin withdrawal. 15 However, if a person is on long-term phenytoin, gingi val overgrowth can make effective oral hygiene difficult and compromises oral health. Treatment options include liai son with the patient's doctor regarding a switch to an alternative anticonvulsant drug and improved oral hygiene. 16 Sur gery can be used to remove the gingival overgrowth but it will recur if phenytoin is still being taken.
Carbamazepine can also cause oral complications including ulceration, xerostomia, glossitis and stomatitis. 4 Sodium valproate can decrease the platelet count and function, resulting in clotting problems, albeit rarely. 4 This is insignificant for minor surgery such as straightforward extractions, but a clot ting screen is advisable before major surgery. 1 Any drug prescribed long term as a syrup-based medicine has the potential to cause dental caries (Fig. 2) . Where this is the case, appropriate pre ventive measures (such as rigorous oral hygiene, use of fl uoride and chlorhexi dine varnishes, gels or pastes, and regu lar dental review) need to be enforced. 1, 17 Alternatively, the medical practitioner could be requested to prescribe a sugar free medicine. 17, 18 A number of medicines used in den tistry can interact with anticonvul sant medication. 7 For example, aspirin and other NSAIDs can interfere with phenytoin metabolism and can increase the bleeding tendency induced by val proate, 5 and metronidazole and anti fungal agents such as fl uconazole and miconazole inhibit the metabolism of phenytoin, increasing its plasma con centration. 7 Care must be taken if either of these anti-fungal agents have to be prescribed and liaison with the physi cian to arrange monitoring of phenytoin levels is advised. 1 
Trauma
Trauma from falls during seizures can cause head injury, subluxation of the temporomandibular joints, dental injury or some other fracture. 4, 5, 19 The key predictor for dental injury is seizure severity, 19 and damage can result in subluxation and avulsion of teeth, frac tures, and loss of vitality. 5 Trauma to anterior teeth should be dealt with in the normal way and composite restora tions should be the first choice of treat ment, as the newer bonding agents and ceramics make large restorations possi ble.
1 If a tooth is avulsed and cannot be accounted for, a chest radiograph may be required. 5 The lips should also be exam ined for tooth fragments when incisors are fractured.
Fixed and removable prosthodontics
The presence of a seizure disorder can influence prosthodontic treatment deci sions. 3 As a general rule, it is safer to use fixed prostheses rather than removable appliances, as the latter can dislodge during a seizure causing oral injury or airway obstruction.
1,3-5 If a denture is unavoidable then a well fi tting, reten tive cobalt chrome prosthesis with metal backings to anterior denture teeth is the type of choice, as it is less likely than acrylic to fracture (Fig. 3) . For full dentures, it has been suggested that either a metal (Fig. 4) or carbon fi bre reinforced base (Fig. 5) is used, or that the denture is constructed from high impact acrylic.
A removable prosthesis may be con tra-indicated in those individuals with severe or poorly controlled seizures and an alternative option is an implant retained bridge or implant-supported overdenture. Radnai et al. 20 describe a case report where a 48-year-old with epilepsy was successfully provided with three short span bridges in the lower jaw supported by six dental implants. 20 As a precaution against damage during sei zures at night he was provided with a bite guard.
Large posterior restorations are prone to fracture in someone who clenches during tonic clonic seizures 1, 3 and full crowns have been suggested as pref erable in posterior quadrants. 1, 3 Fur thermore, full metal crowns should be considered where aesthetically accept able, as they minimize the chance of fracture which is likely with porcelain. 3, 5 When carrying out treatment, a mouth prop attached to a chain may be used throughout as a precautionary measure, and the oral cavity should be kept as free from debris as possible. 5 
Local anaesthesia
Concern has been raised that local anaesthetic agents containing lidocaine can precipitate seizures in people with epilepsy. This is highly unlikely, as although large doses of lidocaine can cause convulsions when given intrave nously, 5, 21 the mechanism of fit caused by lidocaine overdose is quite different from the mechanism of seizures in epilepsy. 21 It is considered safe to use local anaes thetic agents in people with epilepsy. However, it is prudent, as with any patient, to use an aspirating injection technique and not to exceed the recom mended safe dose of anaesthetic agent. 21 
Conscious sedation
Conscious sedation can be useful to reduce dental anxiety that may act as a seizure trigger. 1 There are no contra indications to the use of inhalational sedation with nitrous oxide and oxygen, and intravenous sedation with a benzo diazepine can also be useful. 1, 22 However, when sedating patients whose epilepsy is controlled by benzodiazepines (includ ing clobazam and clonazepam), careful titration of the benzodiazepine against the patient response is advocated as the individual may either have a high tol erance to midazolam, or alternatively they could experience an additive effect leading to over-sedation. 23 In addition, the use of flumazenil, which reverses the effect of the benzodiazepines, should be avoided in this group of patients because of the risk of also reversing the effect of the anti-epileptic drug. 1, 22, 24 Intravenous sedation with propofol is relatively contra-indicated, as it has a neuro-excitatory effect and there have been reports of seizure-like phenomena associated with its use. 25 
General anaesthesia
There are no particular problems associ ated with general anaesthesia, although it is important to maintain anticonvulsant therapy throughout the peri-operative period. 1, 5 Most anaesthetists are happy for patients to take their usual medication (with a small amount of water if necessary) before anaesthesia. People with poorly controlled seizures or with additional medical problems are better treated on an in-patient basis than as day cases.
1,4
Management of a seizure in the dental surgery Epileptic seizures are the third most common medical incident in dental sur geries 16 and the dental team should be trained and prepared to manage such an event. When a seizure occurs, the fi rst step is to protect the individual from further injury by stopping treatment, removing all instrumentation from the mouth, moving all equipment out of reach and reclining the dental chair to the supine position as near to the fl oor as possible. 3 It is not necessary to move the patient onto the floor and indeed, this is practically impossible when they are fitting, especially in the confi ned space of a small surgery. 1 There is no need to restrain the person or place anything in their mouth and furthermore, it is not wise to place fingers into the mouth of a person having a seizure as they may be bitten if the individual clenches during a tonic clonic seizure. The majority of fi ts are self-limiting and the person will recover quite rapidly.
After a seizure some people sleep deeply. Rather than rousing them, place them in the recovery position and moni tor respiration until they wake. They may be disorientated and embarrassed on waking and require reassurance. Once alert, they can go home but must be accompanied. 1 It is important to remember that there are other conditions which should be considered in the differential diagno sis of epilepsy, and these are set out in Table 4 . 1 
Management of prolonged or repeated seizures
If seizures of any type continue una bated for more than fi ve minutes, 26 or if they stop and start again, then they are considered as a separate entity known as 'status epilepticus' and need to be managed accordingly. 27 The emergency services should be called immediately and if the patient is having diffi culty breathing, or is becoming cyanosed, the airway should be maintained by gently extending the neck if possible. 5 People with poorly controlled seizures usually carry emergency medication, however this is often diazepam supposi tories. Whilst this will stop recurrent seizures in 70% of patients, it is an unfa miliar route of administration to dental professionals. 1 Fortunately, midazolam administered by placing it in the buccal sulcus of the oral cavity for absorption through the oral mucosa is becoming more widely used. 26 Midazolam is a recognised fi rst-line drug for the treatment of status epilepti cus, 28 and as a familiar drug to dentists, is suitable for use in dental practice. 5 The administration of 10 mg/2 ml of midazolam intramuscularly 5 into the front of the thigh alleviates the problem of finding a vein in a patient who may • Sleep disorders, eg narcolepsy be exhibiting tonic clonic seizures, and is successful in terminating the major ity of status epilepticus. 1 Alternatively, 10-20 mg of diazepam can be given intramuscularly. 1 It is not necessary to administer oxygen during a fi t of short duration. However, if following drug administration the fi tting continues or restarts, oxygen should be admin istered at 10 litres/min and suction used to remove excess saliva from the mouth and pharynx until the emergency services arrive. 5 All individuals with epilepsy should have a comprehensive care plan that is agreed between them, their family or carers and their primary and second ary care providers, including the dental team. 26 Epilepsy is common and with a carefully taken medical and seizure his tory, and proper training in managing seizures, the primary care dental team should feel confident, and be prepared, to treat most people with the condition.
LATEX ALLERGY
Latex allergy occurs in 1-5% of the gen eral population 29 and is more common in children and young working adults because of the increased medical and/ or occupational exposure to latex over the past two decades. Dental practition ers need to be aware of individuals who may have an increased risk of being latex sensitive, 30 including themselves and their staff, and eliminate, substi tute or control the use of natural rubber latex (NRL) in daily practice as far as possible. 31 Clark 32 reported that general dental practitioners indicated they were prepared to accept patients with latex sensitivities but wanted more informa tion about the latex content of equip ment to be fully aware of the necessary precautions required. Subsequently, good practice guidelines for managing patients with latex allergy were pub lished by the FGDP (UK). 33 Whilst dentists routinely ask patients about allergies there is merit in includ ing screening questions to identify those individuals who have increased poten tial for sensitivity so that routine prac tice can be modifi ed accordingly.
34 Table  5 sets out the groups identified as most likely to develop latex sensitivity. 29, 35 They include up to 10% of rubber indus try workers and up to 14% of paramed ics and emergency department staff. 29 However, by far the highest prevalence of latex allergy is in people with spina bifida, with reports as high as 28-67%. 36 This group may also have a genetic pre disposition to latex sensitisation and with continued exposure to a higher incidence of latex products throughout their lives, have a 1 in 2-4 risk of devel oping latex sensitivity. People with con genital urogenital abnormalities are also at high risk of sensitisation because of early repeated contact with rubber blad der catheters and clinical gloves. 37 Inter estingly, the prevalence of latex allergy is also increased in persons with aller gies to tropical fruits and cross reacting antigens have been found between latex and avocado, kiwi, papaya, peach, nec tarines, bananas, chestnuts and fi gs. 29, 31 All of these patient groups should have a detailed pre-treatment assess ment to identify possibility of latex allergy. Table 6 gives examples of the sort of questions that should be asked. 34 The responses to these questions can be used to categorise the patient's risk and management strategies can be modifi ed accordingly. Diagnosis of latex allergy is via clinical history, medical history, serology and dermatological skin prick tests. Liaison with the patient's derma tologist or allergist can establish the presence and severity of a confi rmed or suspected latex allergy. Field 34 describes three groups of latex allergy risk:
Group one -people with a known history of anaphylaxis to latex. They should only be treated in a dedicated environment which is completely latex screened and where there are prepared staff trained and competent to deal with severe allergic reactions with non-NRL emergency and resuscitation equipment. If the individual carries an adrenaline auto-injector, such as an epi-pen, it should be easily available at all times throughout dental treatment.
Group two -people who have a history of localised type IV reactions to NRL or who have exhibited signs and symptoms such as rhinitis, urticaria or conjunc tivitis. Preferably, they should receive treatment in a latex-free environment. However, in liaison with their allergist/ dermatologist it may be possible for them to be treated in a latex-modifi ed environ ment, for example using latex-and pow der-free gloves, latex-free dam, tefl on amalgam carriers, prophylaxis brushes rather than rubber cups, and local anaes thetic agents in plastic cartridges. Also, appointments should be given early in the day when there are less circulating allergens in the environment.
Group three -people who have not exhibited symptoms of latex allergy but fall into one of the latex sensitive 'at risk' groups. The dental team should be alert to, and recognise any adverse signs of sensitivity.
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• Do you have a history of allergies to drugs, foods, fruits, peanuts, adhesive tape or latex?
• Have you ever experienced a severe allergic reaction?
• Do you have hives or develop itching after contact with things such as balloons, household gloves, elastic bands or condoms?
• Have your lips or tongue ever been swollen following dental treatment?
• Has your face ever been swollen or red following a local anaesthetic?
• Have you ever developed asthma, breathing problems, itching eyes or a runny nose associated with work? The signs and symptoms of an aller gic reaction to NRL are the same as those due to other allergens encountered in the dental practice. 31 It may present as non immunological infl ammation similar to eczema (a type IV delayed response con tact dermatitis) or a full-blown type I NRL allergy, with severity ranging from localised urticaria (hives) and wheez ing to a life threatening anaphylaxis and associated angioedema. The onset of reaction is usually seen between 5 and 60 minutes after exposure. Acute ana phylaxis is a medical emergency and an ambulance should be summoned immedi ately and the paramedic team advised of the latex allergy. 34 Interim management by the dental team will be in accordance with local protocols. Adrenaline is the key drug and can be delivered intramus cularly in a dose of 0.5-1 mg of 1:1,000 concentration. 7 For obvious reasons it is good practice to ensure that the drug box and contents are latex-free.
Full guidelines for dealing with emer gency treatment of anaphylactic reac tions, and frequently asked questions, can be found on the Resusitation Council UK's website. 38, 39 
BISPHOSPHONATES
Bisphosphonates are a class of drugs used increasingly to treat osteoporo sis, multiple myeloma, Paget's disease, osteogenesis imperfecta and malignant bone metastases. The efficacy of these agents in treating and preventing the significant skeletal complications asso ciated with these conditions has had a major positive impact for patients and is responsible for their widespread use in medicine. 40 However, despite these benefits, an increasing body of litera ture suggests that bisphosphonate use, especially of intravenous (IV) prepara tions, is associated with osteonecrosis of the jaws. 41 This results from a complex interplay of reduced osteoclast activity, altered bone metabolism, local trauma, increased demand for bone repair and hypovascularity. 42 To distinguish bisphosphonate-related osteonecrosis of the jaws (BRONJ) from other delayed healing conditions, it has been agreed that patients must have cur rent or previous treatment with a bisphos phonate; exposed, necrotic bone in the maxillofacial region that has persisted for more than eight weeks; and no his tory of radiation therapy to the jaws. The most common presentation is absent or delayed hard or soft tissue healing after dental extractions or surgery. 42 However, BRONJ may present clinically as spon taneous areas of exposed yellow-white hard bone with smooth or ragged bor ders. 41 Patients are usually asymptomatic but may develop severe pain because of secondary infection. 41, 42 In patients who seemingly develop BRONJ spontaneously, there is usually a history of trauma to the oral soft tissues surrounding the area of necrotic bone (Figs 6 and 7) . 42 Bisphosphonates are marketed under the brand names Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid and Zometa. They are delivered orally or intrave nously. Bisphosphonates in tablet form are commonly used to prevent and treat osteoporosis in post-menopausal women. The World Health Organization launched a fracture risk assessment tool which could have a huge impact in reducing the number of people who break bones unnecessarily because of osteoporosis. 43 However, this will no doubt lead to the likelihood of more patient groups being offered preventive treatment for oste oporosis from their primary care practi tioner, including the use of licensed and effective oral bisphosphonate therapy. 44 Bisphosphonates are used intrave nously in the management of hypercal caemia of malignancy, skeletal events related to bone metastases from tumours, and lytic lesions of multiple myeloma. 45 When used in cancer chemotherapy, the drugs are delivered intravenously in high doses and the recipients have the highest potential for developing BRONJ, representing 94% of published cases. 41 Zoledronate (Zometa) and pamidro nate (Aredia) exert several anti-tumour effects and exhibit particularly high potency. 42 Their significant effect on the quality of life for patients with advanced cancer, where disease would otherwise cause bone pain and possibly even spon taneous fractures, 46 means that their benefit is considered to outweigh the risk associated with their use. [40] [41] [42] 46, 47 Table 7 sets out the groups of people who can be treated preventively with bisphosphonates. Some groups who could be treated with oral forms are pre scribed the drug intravenously as com pliance with the use of either weekly or daily oral bisphosphonates is poor. 48 This is in part due to them needing to be taken on an empty stomach with the tablets swallowed whole and the person remaining sitting or standing for at least 30 minutes after taking them. 48 People unable to comply with these restrictions, who have dyspepsia, dysphagia, gastro intestinal malabsorption, or who have reported side-effects such as infl amma tion and ulceration of the oesophagus, stomach pains, nausea and infl ammation of the tongue, are usually considered for intravenous preparations. 44 General dental practitioners have a key role to play in identifying patients at risk of developing BRONJ, educating and advising them, reducing oral risk factors and initiating early specialist referral where BRONJ is suspected. 49 A thorough medical and drug history will highlight potential risk factors enabling dental practitioners to implement suit able preventive measures and manage ment strategies.
Guidance based on expert opinion has been widely published. 41, 42, 45, 46 Most recommended treatment modalities for patients unavoidably undergoing extrac tions or surgical work are based on expert and consensus opinion and reviews of trends in case studies. Effectiveness of bisphosphonate 'drug holidays' prior to surgical intervention, suitable pre-and post-operative antimicrobial regimes, and use of oral disinfectants to prevent infection and aid healing are all await ing evidence from longitudinal studies and clinical trials and remain incon clusive at present. 40, 41, [45] [46] [47] 49 The authors recommend that current guidelines and recommendations should be consulted and followed as they evolve.
The most recent position paper groups the risk factors for the development of BRONJ in three categories: 45 1. Drug-related -potency, choice of bisphosphonate, route of adminis tration, duration of therapy 2. Local -dento-alveolar surgery, anatomy, concomitant infl ammatory oral disease (periodontal and dental infection) 3. Demographic/systemic -age, race, medical co-factors and cancer diagnosis.
What is clear is that prevention of BRONJ is currently the best approach to managing it. 46 To date, most cases have developed in patients receiving intrave nous preparations for the treatment of multiple myeloma or metastatic cancer. 41 Ideally, these patients should have a thor ough oral examination, with any unsal vageable teeth removed and all invasive procedures completed so that optimal oral health is achieved and maintained before bisphosphonate treatment com mences. 45 If this is not possible, the goal should be to achieve this status within six months of commencement of intrave nous bisphosphonate therapy, as anecdo tal evidence points to a low incidence of osteonecrosis occurring in this period. 46 It is critical that patients are appraised of the importance of both oral hygiene and regular dental check-ups. Wherever possible, dento-alveolar surgery includ ing extractions, implant placement, peri apical surgery and periodontal surgery should be avoided in patients taking intravenous bisphosphonates, as they are at least seven times more likely to develop BRONJ than patients who are not having surgery. 42, 45, 46 For non-restorable teeth, decoronation and endodontic treatment of the remaining root(s) is advocated. 50 However, it is of note that the presence of infection and periodontal disease Patients with dentures should be exam ined for any potential areas of mucosal trauma, especially in the lingual fl ange area. Spontaneous necrosis associated with both tori and trauma from dentures has been reported in individuals taking oral bisphosphonates. 41, 45, 51 Therefore, dentures should be reviewed regularly and patients with anatomical features such as tori or pronounced mylohyoid ridges should be monitored vigilantly and specifically instructed to report any pain, swelling or exposed bone. 41, 45 Because bisphosphonates are incor porated into the skeleton without being degraded, they are remarkably persist ent drugs and their estimated half life is at least 10 years. 52 The risk of asso ciated complications seems to increase with the increased time of bisphospho nate use for both oral and IV prepara tions. The risk of developing BRONJ with oral bisphosphonates, while small, appears to increase when their dura tion of use exceeds three years, and the risk increases in the presence of certain co-morbidities such as chronic corticosteroid use, diabetes or the use of chemotherapeutic agents. 45 Currently the degree of risk for osteonecrosis in patients taking oral bisphosphonates is uncertain and warrants careful moni toring. 41 Preventive oral care, including regular radiographic and periodontal review, should be undertaken. This must include patient awareness training of the risks and appearance of BRONJ, and encouragement to report any exposed bone or soft tissue ulceration early on. Kearns 51 suggests that practition ers should consider amending current medical history-taking practice to focus on areas more recently associated with increased use of bisphosphonate ther apy. He warns that patients sometimes do not report medication which is deliv ered intravenously by a physician unless asked specific or direct questions, and that many patients may fail to include a weekly tablet taken for osteoporosis within a list of multiple medications taken daily. 51 In addition, those patients lung cancer, breast cancer and prostate cancer may euphorically omit report ing their ongoing monthly intravenous bisphosphonate injection from their spe cialist team once their chemotherapy has subsided and they are in remission. 51 Bisphosphonate use remains an important area of vigilance for pri mary care practitioners in view of the increasing use of these drugs for groups of patients who are likely to be seen in general practice. The National Institutes of Health announced funding opportu nities for research into BRONJ in 2006. Thus, it is likely that evidence-based information that will allow clinicians to make more accurate judgements about risk, treatment selection and outcomes relevant to patient needs will start to become available. 42, 45 
BLEEDING DISORDERS
A bleeding disorder arises if there is a problem in any part of the haemostatic and clotting pathway and can be acquired or congenital. 53 A carefully taken medi cal history helps establish the likelihood of excessive or prolonged bleeding. Indi cators of a bleeding condition include diagnosis or family history of a bleeding disorder, treatment with anticoagulant medication and liver disease, as well as factors such as abnormal bruising, pro longed bleeding from cuts, nose bleeds, menorrhagia, and previous haemorrhage after dental extractions, childbirth or surgery. 53 Ninety percent of post-opera tive bleeding is the result of local causes and can be stopped using simple meas ures and should not recur. However, when a bleeding disorder is suspected, referral for investigation prior to under taking invasive dental treatment likely to cause bleeding is essential.
53
Acquired bleeding conditions
Acquired bleeding conditions occur as a result of liver disease and platelet disorders (Table 8 ) 54 or as the result of anticoagulant therapy. People who have liver failure and/or alcoholism, renal failure, thrombocytopaenia, and/or are receiving a current course of cytotoxic or chemotherapy will have coagulation and clotting disorders and should not for their condition. 55 
Anticoagulant therapy
A significant proportion of people are on prescribed anticoagulants to provide prophylactic treatment for ischaemic heart disease, myocardial infarction and deep vein thrombosis. This number is growing and the dental team will increasingly have patients who are tak ing anticoagulant drugs that target either platelets or the clotting pathway.
i) Antiplatelet therapy
Commonly used drugs include aspirin and dypiridamol. Many people take 75 mg aspirin daily as a prophylactic meas ure, and this regime does not pose a significant bleeding risk for dental pro cedures. However, when used in com bination, antiplatelet medications have a synergistic effect and impair platelet function for the platelet's lifetime (half life of 8-12 days). 57 Current advice from the UK Medicines Information Serv ice regarding dental treatment is that antiplatelet medications (including aspi rin in combination with clopidogrel) do not have to be stopped or altered before primary care dental surgical procedures and locally applied measures are usually adequate to achieve coagulation. 55 
ii) Coumarin therapy
Warfarin (a vitamin K antagonist) is the most commonly prescribed coumarin. It is used as prophylaxis or treatment for deep vein thrombosis, patients with prosthetic heart valves, and for people with atrial fibrillation. It prolongs both the prothrombin time and the activated partial thromboplastin time and its effects are monitored using the Inter national Normalised Ratio (INR). The usual INR therapeutic range for deep vein thrombosis is 2-3, and up to 4.5 for patients with prosthetic heart valves.
It is considered that people with an INR of 4 or less can safely undergo dental sur gery in general dental practice without any dose adjustment to their warfarin. 56 Current advice is that warfarin is not stopped before dental surgical procedures as the rebound risk of thromboembolism following withdrawal outweighs the risk of oral bleeding. 56 The risks are 1% and 0.2%, respectively. 57 The patient might bleed more than normal but the bleeding is easily controlled with local measures (Table 9) . Warfarin regimes should only be stopped or changed under supervi sion of the anticoagulant clinic and the patient must be discouraged from unilat erally reducing or withdrawing it prior to dental treatment.
Ideally the INR should be checked within the 24 hour period prior to treat ment, ideally on the day of the proce dure. This can be done in the dental surgery using a self-testing machine such as the Coagucheck Monitor. How ever this is not always possible in the primary care setting, and for patients with a stable INR, measurement within 72 hours before the procedure is accept able. 56 Patients normally carry a record card of their INR readings, from which the stability of control and average INR can be obtained. Irregular readings sug gest the INR is poorly controlled. Peo ple with a poorly controlled INR, or an INR >4 who require multiple or diffi cult extractions should be seen in hospital. 56 It is considered safe to scale a patient on anticoagulants provided the INR is <4, although it is prudent to scale around one or two teeth and observe how long haemostasis takes before proceeding further. There is a theoretical risk of bleeding into fascial planes following an inferior dental block and where possible this procedure should be avoided. If its use is unavoidable, an aspirating tech nique should be used and the injection given slowly to minimise tissue dam age. 56 Tranexamic acid mouthwash can be useful for arresting gingival haem orrhage, although its routine use is not necessary for this patient group.
Warfarin interaction with other drugs generally leads to an elevated INR and risk of spontaneous bleeding. All anti biotics affect the INR value to some extent, although single dose amoxicillin has little effect. Metronidazole potenti ates the effect of warfarin and should be avoided if possible. If it is necessary to prescribe antibiotics it is important to consult the haematologist/anticoagu lation clinic so that the INR value can be monitored during antibiotic therapy. Antifungal agents (such as fl uconazole, miconazole and ketoconazole) potentiate the effect of warfarin several fold, even after topical use, and must be avoided. It is prudent to refer to the latest Den tal practitioners' formulary for possible drug interactions before prescribing for patients taking warfarin.
Hereditary or congenital bleeding disorders
Congenital bleeding disorders (CBD) have the potential to cause mild or severe bleeding tendencies. 58 The most common types of CBD, their hereditary pattern and prevalence are set out in Table 10 . Many protocols and guide lines for managing the risk of bleeding following dental treatment have been published and, though few are evidence based, 59 -61 they mostly recommend the use of clotting factor replacement ther apy before invasive dental treatment. The use of careful techniques, local measures (Table 9 ) and appropriate use of antifibrinolytic agents post-operatively has resulted in a reduced need for coag ulation factor replacement prior to inva sive dental treatment, including some
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• Focus on prevention of dental disease
• Regular reviews tailored to the individual's need
• Initial liaison with the person's haemophilia centre to confirm disease severity and management
• Post-operative management with tranexamic acid and local measures
• Judicious planning of procedures likely to cause bleeding to minimise the episodes requiring anti coagulant therapy
To reduce the risk of post-operative bleeding:
• Carry out all procedures with minimal trauma
• Particlarly, carry out any surgical procedures with minimal trauma
• Use a local anaesthetic agent with a vasoconstrictor
• Use haemaostatic agents in sockets, eg oxidised cellulose such as Surgicel, or collagen sponges
• Suture sockets with just enough tension to stabilise gum flaps and avoid clot disturbance • Check INR stability and that the level is <4
• Use of tranexamic acid mouthwash, if available, 4× a day for 2 days
• Avoid prescribing NSAIDs Blood-borne viruses minor oral surgery procedures. 59 Despite ment. 53 Bleeding into the cranium after this, people with CBD face barriers to only a mild injury can lead to death. 53 Patients with CBD were exposed to accessing dental care, for example need ing to travel long distances to special ist dental centres, long waits for access to services, increased treatment needs due to neglect and fear, and the costs, both financial and emotional, associated with these. 62 The majority of patients with CBD can be safely treated in mainstream general dental services or via shared care with a specialist centre where more invasive or surgical procedures are required. 63 Their successful management is the result of co-operation between haematologists and dentists. Gomez-Moreno et al. 58 con ducted an extensive review of the cur rent literature and concluded that the management of people with CBD cannot be based on a single rigid protocol and that each haematological disorder and individual patient requires an individ ualised approach. They recommended that the dental professional must con sider the type of hereditary haematolog ical disorder involved, whether standard dental treatment should be modifi ed, whether factor replacement therapy or drugs are required to carry out dental treatment without risk of haemorrhage, and whether any prescribed drugs are contra-indicated. 58 
Haemophilia A
The severity of haemophilia A is depend ent on the plasma levels of active factor VIII. 5 It is diagnosed via clinical his tory and diagnostic laboratory fi ndings, which are characterised by a normal bleeding time and INR (prothrombin time) but a prolonged activated partial thromboplastin time (APTT) and low levels of factor VIII. Disease is consid ered severe when the plasma level of factor VIII is <1% of normal, moderate if between 2-5% and mild if it is between 6-40%. 62 Haemophilia A typically man ifests in childhood as easy bruising and prolonged bleeding from wounds follow ing injuries. Most people with mild or moderate disease lead relatively normal lives but severe haemophilia results in haemarthrosis, from spontaneous bleed ing into muscles or joints. Recurrent haemarthrosis can result in deformity and, in extreme cases, joint replaceModerate haemophilia is usually only problematic after trauma or surgery, and mild haemophilia may go undiagnosed until an event such as prolonged bleed ing following a dental extraction. 5 The treatment of people with either haemophilia A or B involves the replace ment of the deficient clotting factors (porcine or recombinant) by intravenous infusion to control or prevent bleed ing. In severe cases this necessitates daily injections which most people self administer, improving both quality of life and convenience. 5 The use of factor concentrate is not without its drawbacks, and between 15-25% of people develop inhibitors or antibodies with repeated use, making their condition more diffi cult to control.
von Willebrand's disase (vWD)
In this CBD there is an extended bleed ing time due to poor platelet function and low levels of both circulating von Willebrand factor (vWF) and ristocetin co-factor (which promotes collagen bind ing), as well as low factor VIII activity. 65 vWD is usually characterised by features similar to platelet dysfunction, such as menorrhagia, gastro-intestinal bleeding and purpura of mucous membranes and skin. Gingival bleeding is more common than in haemophilia.
Seventy-five percent of people have mild or Type 1 vWD, which is usually treated using the synthetic hormone desmopressin (DDAVP). This stimulates release of the available vWF from the endothelial cells, producing a temporary rise in both vWF and factor VIII. Desmo pressin is usually given by intravenous infusion over 20 minutes by haemophilia centre staff or a self-administered high strength nasal spray. Tranexamic acid (TA), an anti-fi brinolytic agent used to help stabilise blood clots in minor bleeds, is also useful. It is usually administered in tablet form, but can be given in syrup form or intravenously, 65 and in the den tal situation it can be used as a mouth wash. 66 Some of the more severe types of vWD require factor replacement therapy. Currently, this is derived from human plasma as no recombinant vWF concen trate is yet available.
hepatitis C virus (HCV)
67 from the use of non-inactivated replacement factor concentrates from pooled human blood until 1986, when effective heat treatment was introduced. The presence of HCV in patients with haemophilia has been reported to be at least 70%. 68 A similar situation existed with human immunode ficiency virus (HIV), followed by possible risk from blood products contaminated with vCJD. As many as 4,000 people in the UK, mainly with haemophilia, have been warned by the CJD Incidents Panel that they may be at risk from blood products received before 1999. Viral inactivation of plasma-derived factor concentrates was introduced in the mid-1980s and the use of recombinant (non-human derived) factor concentrates started in the early 1990s. To further avoid viral contamina tion, wherever possible, treatments that avoid the use of blood or blood prod ucts have been developed. These meas ures have reduced, if not removed, the risk of viral or prion transmission with these products. 59 
Modification of dental treatment
Recent guidelines produced by the World Haemophilia Federation 59 conclude that most patients with haemophilia can receive the majority of their routine dental care in the primary care setting follow ing the principles set out in Table 11 . 53, 59 The goal of treatment is to minimise the challenge to the patient by restoring the haemostatic system to acceptable levels and maintaining haemostasis by local and adjunctive methods. 69 Patients with CBD are often anxious about dental treatment on several fronts -the complexity or unpleasantness of treatment itself, unease about disclos ing a medical history which may attract a degree of stigma, and concern about dentists' understanding of their condi tion and its management. 62 Consequently, people may avoid dental treatment until they have a problem and extensive treatment needs 53 and this may account for the higher incidence of dental caries and periodontal disease in patients with bleeding disorders. 70 Spontaneous bleeding has been reported in patients with haemophilia under conditions of emotional stress and it has been advocated that the dental professional should consider the possi bility of bleeding as a result of the stress associated with dental treatment. 58 Con scious sedation using midazolam can be used to control anxiety and possibly prevent haemorrhage, provided care is taken during venepuncture to avoid a haematoma. For this reason, where pos sible, the dorsum of the hand is preferred to the ante-cubital fossa. 22 Precautions need to be taken before invasive dental procedures likely to cause haemorrhage, such as administra tion of an inferior dental block, extrac tions, implants, or periodontal surgery. These procedures need a factor level between 50-75%. As coagulant therapy prior to dental treatment raises the fac tor levels to near normal, with this cover people can receive dental treatment in primary care. 53 The half-life of coagula tion factors needs to be considered when planning treatment. Factor VIII has a half-life of only 10-12 hours and dental treatment needs to be carried out on the day of cover. Although preferable, it is rarely possible for extensive treatment to be completed in one visit. However, treatment should be organised to mini mise the number of factor replacement sessions and thus the likelihood of anti body development. Factor IX has a longer half-life, allowing dental treatment to be carried out on consecutive days under a single dose of replacement therapy. 71 Effective alternatives to factor replace ment prior to dental treatment for people with mild haemophilia and some forms of vWD include the use of desmopressin (DDAVP) and tranexamic acid (Cycloka pron). The latter can be used systemically in a dose of 1 g orally four times a day, or topically as a mouthwash four times a day for up to seven days post-operatively. It can be prescribed for hospital use but is not readily available in the community, although patients may be able to obtain it from their haematology clinic for den tal use. Lee et al., 67 using a double-blind cross-over randomised trial, showed that tranexamic mouthwash after dental scal ing was as effective as factor replacement therapy beforehand in controlling gingi val haemorrhage for people with haemo philia. 66 For all procedures, whether the patient has received prophylactic coagu lant cover or not, care should be taken to minimise trauma. 5, 53, 59, 60 Table 12 sets out some of the considerations required. Healthy periodontal tissue is essential to prevent gingival bleeding, which can be especially troublesome in patients with vWD, during dental treatment.
There are no restrictions regarding the type of local anaesthetic agent used and those with vasoconstrictors may provide additional local haemostasis. A buccal infiltration can be used without any fac tor replacement, but an inferior dental block must only be given after raising clotting factor levels by appropriate replacement therapy as there is a risk of bleeding into the muscles, along with potential airway compromise due to a haematoma in the retromolar or ptery goid space. Similarly, the use of lingual infiltration should be avoided without factor cover as it too carries the risk of a significant haematoma. Intraligamental, papillary or intra-osseous techniques should be considered as alternatives. Buccal infi ltration of articaine has been reported to successfully anaesthetise mandibular molars. 72 If suffi cient pulpal analgesia is provided, this may also pre clude the need for factor replacement.
Local measures are important to mini mise the risk of post-operative bleeding. Any surgery should be carried out with minimal trauma and suturing is desira ble to stabilise gum flaps using the min imum number of sutures. 5 Use of both non-resorbable and resorbable sutures has been advocated. 8, 57 Topical haemo static agents such as oxidised cellulose soaked in tranexamic acid provide rapid haemostasis. Careful post-operative instructions should include a soft or liq uidised diet and the use of tranexamic
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Dental procedure Considerations
Care of soft tissues Regular use of chlorhexidine mouthwash to reduce gingival infl ammation Minimise accidental damage during treatment -apply soft paraffi n wax, use moistened cotton wool rolls to avoid adherence to the mucosa
Restorative treatment
Coagulant cover unnecessary Take care to protect the mucosa with impressions, X-ray fi lms, matrix bands, etc Despite all measures, post-operative haemorrhage may still occur occasion ally following surgery. Patients should be warned of the possibility of haemor rhage, usually 7-12 hours post-opera tively, and instructed to contact their haematology unit or haemophilia centre in the first instance, where they might consider further clotting factor infu sion. The wound should be examined for signs of a tear or trauma and local measures should be used as previously described. Furthermore, the patient should be instructed to bite on gauze soaked in tranexamic acid for at least 10 minutes. 59 If prescribing for patients with congen ital bleeding disorders, there are no con tra-indications to any of the antibiotics from the dental formulary of the British national formulary, from which dentists may prescribe. 53 However, all bleeding tendencies can be aggravated by the use of aspirin or other NSAIDs. Dental pain can usually be controlled with a minor analgesic and better choices are para cetamol or codeine-based products.
Careful history taking and treat ment planning along with providing the patient with appropriate information allows most safety issues in the den tal setting to be pre-empted and either avoided or dealt with in a structured way. Unfortunately, it is not possible to mitigate all dental emergencies, and appropriate staff training that is regu larly updated is essential to prepare the dental team for coping safely with the unexpected event.
